2013
Is bleeding a necessary evil? The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation
Myat A, Ahmad Y, Haldar S, Tantry US, Redwood SR, Gurbel PA, Lip GY. Is bleeding a necessary evil? The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation. Expert Review Of Cardiovascular Therapy 2013, 11: 1029-1049. PMID: 23984927, DOI: 10.1586/14779072.2013.815423.Peer-Reviewed Original ResearchConceptsStroke preventionAntithrombotic therapyAntithrombotic agentsNovel oral anticoagulation agentsAtrial fibrillation guidelinesOral anticoagulation agentsDrug-drug interactionsDirect antidoteAF patientsAnticoagulation monitoringAnticoagulation agentsAtrial fibrillationAbsolute riskAntithrombotic pharmacotherapyRelative riskLower riskStrong recommendationsPatientsThromboembolismPreventionRiskTherapyInherent risksAuthors' knowledgeAgentsRecent Developments in Understanding Epidemiology and Risk Determinants of Atrial Fibrillation as a Cause of Stroke
Ahmad Y, Lip GY, Lane DA. Recent Developments in Understanding Epidemiology and Risk Determinants of Atrial Fibrillation as a Cause of Stroke. Canadian Journal Of Cardiology 2013, 29: s4-s13. PMID: 23790597, DOI: 10.1016/j.cjca.2013.03.009.Peer-Reviewed Original ResearchConceptsDevelopment of AFAtrial fibrillationRisk factorsStroke riskAF patientsOccurrence of AFEffective oral anticoagulationAcute cardiac conditionsCause of strokeLow-risk patientsNovel risk factorsNovel therapeutic targetPublic health consequencesFormal anticoagulationOral anticoagulationRisk patientsPatient cohortCardiac conditionsEpidemic proportionsTherapeutic targetClinical practicePatientsAnticoagulationHealth consequencesRisk determinants
2012
Anticoagulation in Atrial Fibrillation.
Ahmad Y, Lip GY. Anticoagulation in Atrial Fibrillation. Arrhythmia & Electrophysiology Review 2012, 1: 12-16. PMID: 26835023, PMCID: PMC4711491, DOI: 10.15420/aer.2012.1.12.Peer-Reviewed Original ResearchAtrial fibrillationMost thromboembolic complicationsEfficacy of warfarinNew oral anticoagulantsRisk stratification schemesOral anticoagulationAntithrombotic therapyOral anticoagulantsSevere strokeThromboembolic riskThromboembolic complicationsAF patientsAnticoagulant monitoringCommon arrhythmiaNew anticoagulantsWorse outcomesImproved outcomesNew agentsPatientsAF treatmentStratification schemesAnticoagulationDose variabilityAnticoagulantsWarfarin